Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ERTAPENEM

All injection strengths: not a benefit

Other products in the same Health Canada class (J01D) — coverage varies; not interchangeable

  • Cefepime (Maxipime): not a benefit

Ertapenem for Injection · DIN 02492148 · 1g/Vial · powder for injection, vial

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-19
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ertapenem for Injection · DIN 02492148 Manufacturer: Auro Pharma Inc.; listing date 2021-11-30 Health Canada: Marketed since 2021-10-08 · brand ERTAPENEM FOR INJECTION · ATC J01DH03 ERTAPENEM · form Powder for solution · route Intravenous, Intramuscular · ingredients ERTAPENEM (ERTAPENEM SODIUM) 1 G/VIAL · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Ertapenem for Injection: Formulary list price $52.2650/unit (unit not stated in source; not the patient's cost)

Ministry pays: $52.2650 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98213 · Verify on the e-Formulary ↗ (DIN 02492148)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02492148). DIN 02492148: Ertapenem for Injection Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 084000077; group id 133; item number 0224; lccId None; manufacturer id AUR Source form: Inj Pd-Vial Pk; strength: 1g/Vial Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $52.2650; ministry $52.2650 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02492148 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98213
Interchangeable products
Ertapenem for Injection · DIN 02490773 · $52.2650 Ertapenem for Injection · DIN 02496127 · $52.2650 Ertapenem for Injection · DIN 02511150 · $52.2650 Invanz · DIN 02247437 · not recorded
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (08:40 Miscellaneous Anti-Infectives) and how they are covered

Matched class: 08:40 Miscellaneous Anti-Infectives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): CIPROFLOXACIN, LEVOFLOXACIN, MOXIFLOXACIN HYDROCHLORIDE, NORFLOXACIN, SULFAMETHOXAZOLE & TRIMETHOPRIM, TRIMETHOPRIM 08:40 Miscellaneous Anti-Infectives

CEFEPIME

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1g, 2g · Inj Pd-Vial Pk

CIPROFLOXACIN

· 44 products · Limited Use, codes 533 (1), Listed, not a benefit (3), General benefit (40) · strengths: 10g/100mL, 250mg, 500mg, 750mg · Oral Susp, Tab

LEVOFLOXACIN

· 24 products · Listed, not a benefit (2), General benefit (14), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 250mg, 500mg, 750mg · Tab

MOXIFLOXACIN HYDROCHLORIDE

· 12 products · Listed, not a benefit (1), General benefit (11) · strengths: 400mg · Tab

NORFLOXACIN

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 400mg · Tab

SULFAMETHOXAZOLE & TRIMETHOPRIM

· 9 products · Listed, not a benefit (6), General benefit (3) · strengths: 40mg & 8mg/mL, 400mg & 80mg, 800mg & 160mg · O/L, Tab

TRIMETHOPRIM

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 100mg, 200mg · Tab

CIPROFLOXACIN HCL & CIPROFLOXACIN BASE

· 2 products · Listed, not a benefit (1), Limited Use, codes 394 (1) · strengths: 500mg · ER Tab

LINEZOLID

· 6 products · Off-Formulary Interchangeable, not an ODB benefit (2), Listed, not a benefit (1), Limited Use, codes 362, 363, 364 (3) · strengths: 2mg/mL, 600mg · Inj-300mL Pk, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:40
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:18 Antivirals, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS Treatment INVANZ® (ertapenem sodium) is indicated for the treatment of patients with the following moderate to severe infections caused by susceptible strains of the designated microorganisms (see 4 DOSAGE AND ADMINISTRATION).  Complicated intra-abdominal infections due to Escherichia coli, Clostridium clostridioforme, Eubacterium lentum, Peptostreptococcus species, Bacteroides fragilis, Bacteroides distasonis, Bacteroides ovatus, Bacteroides uniformis, or Bacteroides thetaiotaomicron.  Complicated skin and skin structure infections due to Staphylococcus aureus (methicillin- susceptible strain only), Streptococcus pyogenes, Escherichia coli and Peptostreptococcus species, as well as, diabetic foot infections due to Staphylococcus aureus (methicillin-susceptible strain only) and Peptostreptococcus species. INVANZ® has not been studied in diabetic foot infections with concomitant osteomyelitis or severe ischemia (see 14 CLINICAL TRIALS).  Community acquired pneumonia due to Streptococcus pneumoniae (penicillin-susceptible strain only), Haemophilus influenzae (β-lactamase negative strain only), or Moraxella catarrhalis.  Comp… https://pdf.hres.ca/dpd_pm/00066189.PDF PM date: MAY 12, 2003 Source product: INVANZ; DIN 02247437; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Ertapenem for Injection: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026